Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

Criteria for inclusion: * Patients with a histological or cytological verified adenocarcinoma of the colon or rectum with non-resectable or metastatic cancer. * Patients with measurable disease without previous radiotherapy * Patients with metastatic colorectal cancer with progression after previous therapy with 5-fluoropyrimidines, oxaliplatin or irinotecan. Patients should have been treated with oxaliplatin, but if oxaliplatin has be contraindicated or not tolerated the patient can participate in the trial. * Patients with KRAS-mutation in their primary tumour or metastasis. * Patients with progression after therapy with irinotecan or cetuximab independent of KRAS mutation status. * Previous radiotherapy is allowed to less than 25 % of the bone marrow. * Age more or equal to 18 years. * Performance status less than 3. * An expected survival time of at least 3 months. * Signed informed consent according to specifications from the ethical comites. Criteria for exclusion: * Former or other concurrent malignant disease except treated basal cell carcinoma or in situ cervical cancer. * No cytotoxic therapy or other experimental treatment within 28 days before inclusion. * No former therapy with everolimus or other rapamycin as sirolimus or temsirolimus. * No known hypersensitivity for one or more components in the therapy. * No uncontrolled diabetes * No serious non-healing wounds, gastric ulcers, bone fractures, greater surgical procedures, major traumatic injuries within 28 days before inclusion. * No ongoing bleeding or pathological condition associated with a risk of bleeding. * No liver disease as cirrhose, chronical active hepatitis or chronic persistent hepatitis. * No gastrointestinal disturbances in function that might cause a major change in the absorption of everolimus as ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome. * No planned immunisation with attenuated virus in the study period. * Patients that is unable to follow treatment or evaluation plan. * Every condition or therapy that after the judgement of investigator might infer the patient a risk or influence the trials objective. * Pregnant or breastfeeding women. * At fertile women this is insured by a negative test of pregnancy or use of a safe anticonception during the trial period and at least 3 months after end of treatment. * Patients with active infections or other serious medical co-morbidity, that might prevent the patient from being treated with the protocoled therapy. * Incapacitated